AKAP95

AKAP95
Name	AKAP95
Uniprot	Q02952
Genes	AKAP8
Organism	Homo sapiens

AKAP95 is a human A-kinase anchoring protein implicated in nuclear scaffolding, chromatin condensation, and RNA metabolism. Identified through biochemical fractionation and genetic screens, it interacts with multiple nuclear factors and integrates signaling pathways with chromatin and spliceosomal machinery. AKAP95 contributes to cell cycle progression and is studied in contexts ranging from development to cancer and neurodegeneration.

Structure and biochemical properties

AKAP95 is a 700–800 amino acid protein encoded by the AKAP8 gene and contains modular regions that mediate protein–protein interactions, including an N-terminal dimerization domain and C-terminal regions enriched in basic residues. Structural studies and domain mapping involving techniques used by groups at Cold Spring Harbor Laboratory, Max Planck Institute, Harvard Medical School, Stanford University, and Massachusetts Institute of Technology identify helical motifs, low-complexity sequences, and putative nuclear localization signals. Biochemical assays performed by teams at National Institutes of Health, European Molecular Biology Laboratory, Salk Institute, Broad Institute, and Howard Hughes Medical Institute characterize its binding affinities for regulatory enzymes, phosphorylation sites responsive to Protein kinase A and cyclin-dependent kinases cataloged in databases maintained by UniProt, NCBI, Ensembl, GeneCards, and PDB. Mass spectrometry datasets from consortia including ProteomeXchange, PRIDE Archive, CPTAC, ENCODE Project Consortium, and GTEx Project report post-translational modifications such as phosphorylation, acetylation, and methylation that modulate interactions with factors studied at Johns Hopkins University, University of Cambridge, Yale University, UCSF, and Imperial College London.

Cellular localization and interactions

AKAP95 localizes predominantly to the nucleus, concentrating at chromatin-rich regions, nuclear speckles, and nucleolar peripheries as shown by imaging from labs at Cold Spring Harbor Laboratory, Max Planck Institute for Molecular Cell Biology and Genetics, Wadsworth Center, Beth Israel Deaconess Medical Center, and University of California, Berkeley. Co-immunoprecipitation and proximity labeling experiments from investigators at Rockefeller University, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Ludwig Institute for Cancer Research, and Wellcome Sanger Institute reveal interactions with nuclear matrix components, lamins characterized by work at NIH and University of Oxford, transcription factors studied at University of Chicago and University of Pennsylvania, histone-modifying complexes characterized at Cold Spring Harbor Laboratory and Broad Institute, and spliceosomal proteins cataloged by EMBL-EBI and Max Planck. Partnerships include binding to regulatory proteins characterized in research from University of Toronto, Karolinska Institutet, Seoul National University, Peking University, and University of Melbourne.

Roles in chromatin regulation and transcription

AKAP95 influences chromatin structure and transcriptional output through interactions with chromatin remodelers and histone modifiers mapped by consortia such as ENCODE Project Consortium and Roadmap Epigenomics Project. Studies at Harvard Medical School, University College London, Cold Spring Harbor Laboratory, University of Cambridge, and University of California, San Diego demonstrate AKAP95 recruitment to promoters and enhancers where it coordinates with transcriptional activators and repressors identified in work from Stanford University, Yale University, Princeton University, ETH Zurich, and University of Michigan. Functional genomics approaches from Broad Institute, Wellcome Sanger Institute, European Bioinformatics Institute, Johns Hopkins University, and Columbia University show AKAP95 modulates nucleosome occupancy and chromatin looping, acting in concert with complexes also studied at Max Planck Institute and Salk Institute to influence gene programs regulated during development examined at Cold Spring Harbor Laboratory and Weizmann Institute.

Functions in RNA processing and splicing

AKAP95 associates with components of the spliceosome and RNA-binding proteins, linking nuclear architecture to pre-mRNA splicing as reported by investigators at University of California, San Diego, University of Toronto, Massachusetts General Hospital, Mount Sinai School of Medicine, and University of Cambridge. RNA immunoprecipitation and CLIP-seq datasets from consortia including ENCODE Project Consortium and labs at Rockefeller University and Broad Institute document AKAP95 proximity to nascent transcripts and alternative exons studied in contexts such as neuronal differentiation at Stanford University and immune cell activation at University of Pennsylvania. Cross-talk with RNA helicases and components characterized by Max Planck Institute and National Institute of Allergy and Infectious Diseases places AKAP95 as a scaffold coordinating spliceosomal assembly and kinetic coupling between transcription and splicing reported by teams at Harvard Medical School and Yale University.

Involvement in cell cycle regulation and mitosis

Functional studies from Johns Hopkins University, University of California, San Francisco, Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute, and National Cancer Institute implicate AKAP95 in S-phase progression, G2–M transition, and mitotic chromatin condensation. AKAP95 binds regulators including cyclins and cyclin-dependent kinases characterized by NIH programs and proteomic initiatives at CPTAC, coordinating phosphorylation events that alter chromatin compaction and mitotic spindle-associated processes observed in imaging cores at Max Planck Institute and Harvard Medical School. Loss-of-function studies in cell lines used at Memorial Sloan Kettering Cancer Center, UCSF, University of Toronto, Seoul National University, and Peking University produce defects in chromosome segregation and cytokinesis, linking AKAP95 to checkpoints and repair pathways explored at Cold Spring Harbor Laboratory and Wellcome Sanger Institute.

Clinical significance and disease associations

Altered expression or mutation of AKAP8/AKAP95 has been reported in studies of cancer, including datasets from The Cancer Genome Atlas, cBioPortal, Cancer Cell, Nature Medicine, and clinical centers at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Associations appear in malignancies investigated at Dana-Farber Cancer Institute, Vanderbilt University Medical Center, Mayo Clinic, Cleveland Clinic, and University of Texas MD Anderson Cancer Center with roles proposed in tumor cell proliferation and therapy response. Links to neurodevelopmental and neurodegenerative disorders emerge from cohort studies at Broad Institute, Massachusetts General Hospital, Scripps Research Institute, Karolinska Institutet, and University of California, San Diego that examine splicing dysregulation and chromatin pathology. AKAP95-related pathways intersect with signaling pathways targeted by drugs developed at Roche, Novartis, Pfizer, GlaxoSmithKline, and AstraZeneca and are considered in biomarker studies at Genentech and translational programs at Wellcome Trust. Continued research across academic medical centers and biotech companies refines its potential as a diagnostic or therapeutic node.

Category:Proteins